Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NeuCyte, Inc.

https://www.neucyte.com

Latest From NeuCyte, Inc.

Finance Watch: Insilico Raises $255m To Take AI-Discovered Drugs Into The Clinic

Private Company Edition: Nine new venture capital mega-rounds include Insilico’s series C, $250m from Blackstone for a CAR-T therapy spinout from Intellia and a $210m series B round for Umoja.

Financing Innovation

Deal Watch: Genentech Gets Access To X-Chem’s DNA-Encoded Library Technology

Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.

Deals Business Strategies

Candel Aims High In Next Stage Of Cancer Immunotherapy Mission

Emerging Company Profile: Candel Therapeutics, formerly known as Advantagene, has hired a new leadership team and is aiming for a Phase III data read-out in prostate cancer in 2023.

Emerging Company Profile Companies

Pacts In Medtech: BI, Inflammasome Work On Retinal Disease; Takeda And Prometheus Take On IBD

Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, research and development partnerships and commercial collaborations. This edition covers industry pacts that were signed in September and October 2019.

Pacts in Medtech Deals
See All

Company Information

  • Industry
  • Biotechnology
UsernamePublicRestriction

Register